AllianceBernstein Holding L.P. (AB - Free Report) has announced assets under management (AUM) for March 2019. The company’s preliminary month-end AUM of $555 billion increased 1.5% from the prior month.
Market appreciation and total net inflows were the primary reasons for this rise in total AUM.
At the end of the reported month, AllianceBernstein’s Equity AUM grew sequentially to $211 billion. Further, Fixed Income AUM increased nearly 1.8% from February 2019 to $281 billion. Others AUM (including certain multi-asset services and solutions, and certain alternative investments) increased 3.3% to $63 billion.
By channel, month-end Institutions AUM of $257 billion increased 1.6% from the February 2019 level. Moreover, Retail AUM increased 1.5% sequentially to $202 billion. Private Wealth AUM also rose 1.1% to $96 billion.
Improvement in AUM and growth in revenues are expected to support AllianceBernstein’s financials. So far this year, the stock has rallied 7.4%, underperforming the industry’s growth of 16.9%.
AllianceBernstein currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Asset Managers
Franklin Resources (BEN - Free Report) announced preliminary AUM by its subsidiaries of $712.3 billion for March 2019. Results displayed a marginal decline from $714.2 billion recorded as of Feb 28, 2019. Net outflows, partially offset by positive market change and others, led to this fall.
Cohen & Steers (CNS - Free Report) reported preliminary AUM of $62.6 billion as of Mar 31, 2019, up 3% from the prior month. Market appreciation of $1.9 billion and net inflows of $251 million supported AUM growth.
Invesco’s (IVZ - Free Report) preliminary month-end AUM was $954.8 billion as of Mar 31, 2019, which increased 1% from the prior month. Favorable market returns, non-management fee earning AUM inflows and reinvested distributions were the main reasons for this rise.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>